Although these CX3CR1+ CD8+ T cells may remain in circulation and not infiltrate the tumor microenvironment (TME) in the absence of CX3CL1 production, their presence in peripheral blood may still serve as a valuable indicator of therapeutic response [81]. Here, CX3CR1 is linked to neoplasm.